Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD

3.2  +0.05 (+1.59%)

After market: 3.15 -0.05 (-1.56%)

Fundamental Rating

2

Overall MYNZ gets a fundamental rating of 2 out of 10. We evaluated MYNZ against 568 industry peers in the Biotechnology industry. MYNZ has a bad profitability rating. Also its financial health evaluation is rather negative. MYNZ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MYNZ has reported negative net income.
In the past year MYNZ has reported a negative cash flow from operations.
In the past 5 years MYNZ always reported negative net income.
MYNZ had a negative operating cash flow in each of the past 5 years.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of MYNZ (-163.55%) is worse than 85.74% of its industry peers.
MYNZ has a Return On Equity of -358.07%. This is in the lower half of the industry: MYNZ underperforms 75.88% of its industry peers.
Industry RankSector Rank
ROA -163.55%
ROE -358.07%
ROIC N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

MYNZ's Gross Margin of 64.31% is fine compared to the rest of the industry. MYNZ outperforms 79.58% of its industry peers.
MYNZ's Gross Margin has improved in the last couple of years.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYNZ has more shares outstanding
MYNZ has less shares outstanding than it did 5 years ago.
The debt/assets ratio for MYNZ has been reduced compared to a year ago.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -10.45, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.
MYNZ has a worse Altman-Z score (-10.45) than 75.00% of its industry peers.
MYNZ has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.14, MYNZ is doing worse than 67.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -10.45
ROIC/WACCN/A
WACC7.04%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

MYNZ has a Current Ratio of 1.32. This is a normal value and indicates that MYNZ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.32, MYNZ is doing worse than 83.80% of the companies in the same industry.
A Quick Ratio of 1.26 indicates that MYNZ should not have too much problems paying its short term obligations.
MYNZ has a worse Quick ratio (1.26) than 83.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 1.26
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.47% over the past year.
MYNZ shows a decrease in Revenue. In the last year, the revenue decreased by -0.17%.
Measured over the past years, MYNZ shows a very strong growth in Revenue. The Revenue has been growing by 26.14% on average per year.
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.99%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%74.39%

3.2 Future

MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.
Based on estimates for the next years, MYNZ will show a very strong growth in Revenue. The Revenue will grow by 133.88% on average per year.
EPS Next Y61.96%
EPS Next 2Y37.51%
EPS Next 3Y23.52%
EPS Next 5Y15.04%
Revenue Next Year18.01%
Revenue Next 2Y4.51%
Revenue Next 3Y37.27%
Revenue Next 5Y133.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MYNZ. In the last year negative earnings were reported.
Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as MYNZ's earnings are expected to grow with 23.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.51%
EPS Next 3Y23.52%

More info and screens

0

5. Dividend

5.1 Amount

MYNZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAINZ BIOMED NV

NASDAQ:MYNZ (4/24/2025, 8:27:27 PM)

After market: 3.15 -0.05 (-1.56%)

3.2

+0.05 (+1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01 2025-04-01/amc
Earnings (Next)N/A N/A
Inst Owners11.06%
Inst Owner ChangeN/A
Ins Owners4.07%
Ins Owner ChangeN/A
Market Cap7.42M
Analysts80
Price Target14.28 (346.25%)
Short Float %3.78%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)600%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)28.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.3
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 2.45
EV/EBITDA N/A
EPS(TTM)-22.36
EYN/A
EPS(NY)-6.68
Fwd EYN/A
FCF(TTM)-7.48
FCFYN/A
OCF(TTM)-7.37
OCFYN/A
SpS0.39
BVpS2.61
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -163.55%
ROE -358.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.31%
FCFM N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.07%
Cap/Sales 28.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 1.26
Altman-Z -10.45
F-Score6
WACC7.04%
ROIC/WACCN/A
Cap/Depr(3y)139.31%
Cap/Depr(5y)92.63%
Cap/Sales(3y)121.7%
Cap/Sales(5y)74.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.99%
EPS Next Y61.96%
EPS Next 2Y37.51%
EPS Next 3Y23.52%
EPS Next 5Y15.04%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%74.39%
Revenue Next Year18.01%
Revenue Next 2Y4.51%
Revenue Next 3Y37.27%
Revenue Next 5Y133.88%
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.1%
OCF growth 3YN/A
OCF growth 5YN/A